1. Q7 Hereditary Gynecologic Cancers
Combines oral contraceptive pills have protective effect against Ovarian Cancer in BRCA1 Carriers
Oral contraceptive use, mainly Combined Oral Contraceptive use is associated with reduced risk of ovarian cancer with use, proportional to the duration
of use. The evidence is stronger for BRCA1 carriers but exists for both BRCA1 and
BRCA2 ( Source- FSRH Guideline on COC). But the UKMEC also states that for carriers of known gene mutations associated with breast cancer
(e.g. BRCA mutations) the risks of using CHC generally outweigh the advantages.
COCs are UKMEK 3 for BRCA 1 carriers.
